Future treatment option for hepatocellular carcinoma: A focus on brivanib

Digestive Diseases

Volumn 29, Issue 3, 2011, Pages 316-320

  Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brivanib; Hepatocellular carcinoma; Molecular targeted therapy; Sorafenib

Indexed keywords

BRIVANIB; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ALGORITHM; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER INVASION; CHEMOEMBOLIZATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; POSTMARKETING SURVEILLANCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ALANINE; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051728375     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000327568     Document Type: Conference Paper

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. El Serag HB, Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576. (Pubitemid 46890874)
3. Cancer Statistics in Japan 2009. Tokyo, Foundation for Promotion of Cancer Research, 2009.
4. Takayasu K, Choi BI, Wang CK, et al: First international symposium of current issues for nationwide survey of primary liver cancer in Korea, Taiwan and Japan. Jpn J Clin Oncol 2007; 37: 233-240. (Pubitemid 47090700)
5. Yuen MF, Hou JL, Chutaputti A: Hepatocellular carcinoma in the Asia-Pacific region. J Gastroenterol Hepatol 2009; 24: 346-353.
6. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: Consensusbased clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72(suppl 1):2-15. (Pubitemid 350256660)
7. Makuuchi M, Kokudo N, Arii S, Igaki H, Ikai I, Kaneko S, Kawasaki S, Kudo M, Matsuyama Y, Ohtomo K, et al: Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma. Hepatol Res 2010; 40 (suppl 1):1-144.
8. Xiao EH, Guo D, Bian DJ: Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. World J Gastroenterol 2009; 15: 4582-4586.
9. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
10. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
11. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159-165. (Pubitemid 350239045)
12. Je Y, Schutz FA, Choueiri TK: Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. Lancet Oncol 2009; 10: 967-974.
13. Kudo M: The 2008 Okuda Lecture. Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010; 25: 439-452.
14. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, et al: Management of hepatocellular carcinoma. Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology, 2009. Hepatol Res 2010; 40: 667-685.
15. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M; for the HCC Expert Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29:339-364.
16. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
17. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95. (Pubitemid 46075199)
18. Kopetz S, Hoff PM, Eng MJ, et al: Angiogenic cytokines are increased prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab. ASCO Gastrointestinal Cancers Symposium, San Francisco, January 15-17, 2009, abstr 292.
19. El Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N: The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 2001; 7: 1299-1305. (Pubitemid 32708684)
20. Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J: Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001; 182: 298-304. (Pubitemid 32918381)
21. Huynh H, Ngo VC, Fargnoli J, et al: Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 6146-6153.
22. Bhide RS, Lombardo LJ, Hunt JT, et al: The antiangiogenic activity in xenograft models of brivanib alaninate, a dual inhibitor of VEGFR-2 and FGFR-1 kinases. Mol Cancer Ther 2010; 9: 369-378.
23. Raoul JL, Finn R, Kang YK, et al: An openlabel phase II study of first-and second-line treatment with brivanib in patients with hepatocellular carcinoma. ASCO General Meeting, Orlando, May 29-June 2, 2009, abstr 4577.
24. Raoul JL, Finn R, Kang YK, et al: Phase 2 study of first-and second-line treatment with brivanib in patients with hepatocellular carcinoma. ILCA Third Annual Conference, Milan, September 4-6, 2009, abstr O-030.
25. Chao Y, Kang YK, Park JW, et al: Phase 2 study of first-and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). 12th Chinese Society for Clinical Oncology Annual Meeting, Xiamen, China, October 14-18, 2009.
26. Park JW, Harris R, Barrett B, Baudelet C, Walters I: A subanalysis of Asian and non-Asian patients with hepatocellular carcinoma treated in a phase 2 safety and efficacy study of brivanib as first-line therapy. Asian Pacific Association for the Study of the Liver (APASL), Hong Kong, April 13-16, 2009, abstr PE255.
27. Garrett C, Siu L, El-Khoueiry A, et al: A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who failed prior therapy. J Clin Oncol 2008; 26 (suppl):abstr 4111.
28. Wang X, Syed S, Masson E, Walters I, Amit A, Zhang L: Characterization of brivanib pharmacokinetics in Asian and non-Asian subjects with advanced or metastatic solid tumors. Asian Pacific Association for the Study of the Liver (APASL), Hong Kong, April 13-16, 2009, abstr PE256.
29. Hironaka S, Onozawa Y, Aramaki T, et al: Phase 1 study of brivanib alaninate, a novel FGF and VEGF receptor inhibitor. Japanese Society for Clinical Oncology (JSCO) Annual Conference, Yokohama, October 22-24, 2009, abstr OS036-3.